Malignant ascites - New concepts in pathophysiology, diagnosis, and management

被引:53
作者
Aslam, N [1 ]
Marino, CR
机构
[1] Univ Tennessee, Ctr Hlth Sci, Dept Med, Knoxville, TN 37996 USA
[2] Vet Affairs Med Ctr, Med Serv, Memphis, TN USA
关键词
D O I
10.1001/archinte.161.22.2733
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Malignant ascites is a manifestation of advanced malignant disease that is associated with significant morbidity. Mainstays of treatment include diuretics and recurrent large volume paracentesis. Although lymphatic obstruction has been considered the major pathophysiologic mechanism behind its formation, recent evidence suggests that immune modulators, vascular permeability factors, and metalloproteinases are contributing significantly to the process. These new observations offer the opportunity for development of new, more targeted therapies for the treatment of malignant ascites. This article uses a clinical case to highlight the problem, then reviews these new concepts in the pathophysiology of malignant ascites formation. The diagnosis and management of this challenging medical problem are subsequently discussed, with emphasis on how these new pathophysiologic insights are being applied to the development of novel therapies that may soon change how we manage this troubling clinical condition.
引用
收藏
页码:2733 / 2737
页数:5
相关论文
共 29 条
[21]   PHASE-I CLINICAL AND PHARMACOLOGICAL STUDY OF INTRAPERITONEAL CISPLATIN AND FLUOROURACIL IN PATIENTS WITH ADVANCED INTRAABDOMINAL CANCER [J].
SCHILSKY, RL ;
CHOI, KE ;
GRAYHACK, J ;
GRIMMER, D ;
GUARNIERI, C ;
FULLEM, L .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (12) :2054-2061
[22]   PERITONEOVENOUS SHUNTS FOR PALLIATION OF THE PATIENT WITH MALIGNANT ASCITES [J].
SCHUMACHER, DL ;
SACLARIDES, TJ ;
STAREN, ED .
ANNALS OF SURGICAL ONCOLOGY, 1994, 1 (05) :378-381
[23]   EVALUATION OF FIBRONECTIN AS A MARKER OF MALIGNANT ASCITES [J].
SIDDIQUI, RA ;
KOCHHAR, R ;
SINGH, V ;
RAJWANSHI, A ;
GOENKA, MK ;
MEHTA, SK .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1992, 7 (02) :161-164
[24]  
STUART GCE, 1993, CANCER, V71, P2027, DOI 10.1002/1097-0142(19930315)71:6<2027::AID-CNCR2820710617>3.0.CO
[25]  
2-C
[26]   Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: Can the risk be reduced? [J].
van Dam, PA ;
DeCloedt, J ;
Tjalma, WAA ;
Buytaert, P ;
Becquart, D ;
Vergote, IB .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 181 (03) :536-541
[27]  
Verheul H M, 2000, Oncologist, V5 Suppl 1, P45
[28]  
Xu L, 2000, INT J ONCOL, V16, P445
[29]   Markedly elevated levels of vascular endothelial growth factor in malignant ascites [J].
Zebrowski, BK ;
Liu, WB ;
Ramirez, K ;
Akagi, Y ;
Mills, GB ;
Ellis, LM .
ANNALS OF SURGICAL ONCOLOGY, 1999, 6 (04) :373-378